Aimei Health Technology (NASDAQ:AFJK) Upgraded by Wall Street Zen to “Sell” Rating

Wall Street Zen upgraded shares of Aimei Health Technology (NASDAQ:AFJK) to a sell rating in a report issued on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings downgraded Aimei Health Technology from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, August 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat, Aimei Health Technology presently has a consensus rating of “Sell”.

Aimei Health Technology Stock Up 0.1%

AFJK opened at $12.10 on Friday. The firm has a 50 day moving average price of $12.10 and a 200-day moving average price of $26.95. Aimei Health Technology has a twelve month low of $6.75 and a twelve month high of $130.37. The stock has a market capitalization of $38.36 million, a price-to-earnings ratio of 201.70 and a beta of 0.85.

Aimei Health Technology (NASDAQ:AFJK) last issued its earnings results on Thursday, August 13th. The company reported ($0.03) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Aimei Health Technology

A hedge fund recently raised its position in Aimei Health Technology stock. Clear Street Group Inc. increased its stake in Aimei Health Technology Co., Ltd. (NASDAQ:AFJK) by 36.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 83,337 shares of the company’s stock after purchasing an additional 22,294 shares during the quarter. Clear Street Group Inc. owned approximately 1.36% of Aimei Health Technology worth $5,334,000 at the end of the most recent quarter. Institutional investors own 45.58% of the company’s stock.

Aimei Health Technology Company Profile

Aimei Health Technology Co, Ltd. (NASDAQ: AFJK) is a special purpose acquisition company (SPAC). Rather than operating a traditional health-care business, the company was established to identify and complete a merger, acquisition, or similar business combination with an operating company.

The company’s stated focus is expected to include businesses in the health-care and health-technology sectors. Before completing a transaction, Aimei Health Technology does not have a broad portfolio of products or services and may have limited operating activity beyond pursuing a suitable target and managing its corporate structure.

Aimei Health Technology is incorporated in the Cayman Islands and trades in the United States.